Cas:75232-02-9 5-mercapto-1,2,3-triazole monosodium salt manufacturer & supplier

We serve Chemical Name:5-mercapto-1,2,3-triazole monosodium salt CAS:75232-02-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-mercapto-1,2,3-triazole monosodium salt

Chemical Name:5-mercapto-1,2,3-triazole monosodium salt
CAS.NO:75232-02-9
Synonyms:TAS;5-MT;5-MERCAPTO-1,2,3-TRIAZOLE SODIUM SALT;triazolinethione;1H-1,2,3-TRIAZOLE-5-THIOL SODIUM SALT;MFCD00044799;5-MERCAPTO-1H-1,2,3-TRIAZOLE SODIUM SALT;EINECS 261-568-5
Molecular Formula:C2H2N3NaS
Molecular Weight:123.11200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:41.57000
Exact Mass:122.98700
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like TAS chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 261-568-5 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-MERCAPTO-1H-1,2,3-TRIAZOLE SODIUM SALT Use and application,MFCD00044799 technical grade,usp/ep/jp grade.


Related News: Cholesterol drug Crestor, blood thinner Brilinta and acid reflux med Nexium have all suffered as a result. Brilinta, for example, saw emerging markets sales drop 40% at constant currencies to $180 million in the first six months of 2021. 2,2-dibromo-1-((trimethylsilyl)oxy)-2-hydrophosphindol-3-one 1-oxide manufacturers Earlier this year, the company revealed it had broken ground on a 38,000-square-foot commercial cell therapy plant in Lexington, Massachusetts, which is about 10 miles from downtown Boston. Takeda says the new $84 million plant will be used to make cell therapies for cancers and other diseases. 5-methyl-7-phenyl-1,4-dihydro-1H-3λ4-thieno[3,4-d][2,3]-oxathiin-3-oxide suppliers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. 1-(3-(2-chlorophenyl)-6-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1,2,4-triazin-4(5H)-yl)ethan-1-one vendor & factory.